Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster
What would Jonas Salk say if he were here right now? And how do you know when an ALS treatment is working? Find out on the latest episode of "The…
What would Jonas Salk say if he were here right now? How do you know when an ALS treatment is working? And what can pharma CEOs learn from Mr. Rogers?
We cover all that and more this week on the 251st episode of “The Readout LOUD,” STAT’s biotech podcast. We discuss the theatrical merits and actual implications of Moderna CEO Stéphane Bancel’s appearance before a committee led by Sen. Bernie Sanders. We also talk about the latest news in the life sciences, including Regeneron Pharmaceuticals’ latest data for its powerhouse drug Dupixent, an about-face for Sarepta Therapeutics, and how the FDA appears to view biomarkers in neurological diseases.
What's Your Reaction?
